| US7196164B2 (en) | 1997-07-08 | 2007-03-27 | Human Genome Sciences, Inc. | Secreted protein HHTLF25 |
| JP2002513295A (en) | 1997-07-08 | 2002-05-08 | ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド | 123 human secreted proteins |
| US20060052321A1 (en) | 2002-04-05 | 2006-03-09 | Raitano Arthur B | Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer |
| US20030149531A1 (en) | 2000-12-06 | 2003-08-07 | Hubert Rene S. | Serpentine transmembrane antigens expressed in human cancers and uses thereof |
| US6833438B1 (en) | 1999-06-01 | 2004-12-21 | Agensys, Inc. | Serpentine transmembrane antigens expressed in human cancers and uses thereof |
| DE69941187D1 (en) | 1998-06-01 | 2009-09-10 | Agensys Inc | SERPENTINTRANSMEMBRANANTIGENE EXPRESSED IN HUMAN CANCER AND ITS USES |
| US20040141975A1 (en) | 1998-06-01 | 2004-07-22 | Raitano Arthur B. | Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer |
| CZ20012548A3 (en) | 1999-01-15 | 2001-10-17 | Biogen, Inc. | Antagonists of TWEAK and of TWEAK receptor and their use to treat immunological disorders |
| EP1666490A3 (en)* | 2000-07-25 | 2006-11-02 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US7291719B2 (en) | 2000-07-25 | 2007-11-06 | Genentech, Inc. | PRO4332 antibodies |
| JP2004528823A (en) | 2000-10-31 | 2004-09-24 | ディアデクサス インコーポレーテッド | Compositions and methods for colon-specific genes and proteins |
| US20020111302A1 (en)* | 2000-11-30 | 2002-08-15 | Y. Tom Tang | Novel nucleic acids and polypeptides |
| CA2443123A1 (en) | 2001-04-10 | 2002-10-24 | Agensys, Inc. | Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers |
| US20030125521A1 (en) | 2001-06-20 | 2003-07-03 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
| CA2459318C (en) | 2001-09-06 | 2017-09-26 | Agensys, Inc. | Nucleic acid and corresponding protein entitled steap-1 useful in treatment and detection of cancer |
| US7494646B2 (en) | 2001-09-06 | 2009-02-24 | Agensys, Inc. | Antibodies and molecules derived therefrom that bind to STEAP-1 proteins |
| JPWO2003033727A1 (en) | 2001-10-12 | 2005-02-03 | 山之内製薬株式会社 | Cell death inhibitor screening method |
| CN103536916B (en) | 2002-04-09 | 2016-08-17 | 比奥根Ma公司 | For the method treating TWEAK associated conditions |
| AU2003900747A0 (en)* | 2003-02-18 | 2003-03-06 | Garvan Institute Of Medical Research | Diagnosis and treatment of pancreatic cancer |
| US20050025763A1 (en) | 2003-05-08 | 2005-02-03 | Protein Design Laboratories, Inc. | Therapeutic use of anti-CS1 antibodies |
| US7709610B2 (en) | 2003-05-08 | 2010-05-04 | Facet Biotech Corporation | Therapeutic use of anti-CS1 antibodies |
| WO2005019258A2 (en)* | 2003-08-11 | 2005-03-03 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| EP1670947B1 (en) | 2003-09-23 | 2015-04-01 | University Of North Carolina At Chapel Hill | Methods and compositions for the correlation of single nucleotide polymorphisms in the vitamin k epoxide reductase gene and warfarin dosage |
| WO2006101474A1 (en) | 2005-03-15 | 2006-09-28 | University Of North Carolina At Chapel Hill | Methods and compositions for producing active vitamin k-dependent proteins |
| CA2542017A1 (en)* | 2003-10-14 | 2005-05-06 | Baxter International, Inc. | Vitamin k epoxide recycling polypeptide vkorc1, a therapeutic target of coumarin and their derivatives |
| EP1714154A2 (en)* | 2004-02-03 | 2006-10-25 | Bayer HealthCare AG | Diagnostics and therapeutics for diseases associated with plasma glutamate carboxypeptidase (pgcp) |
| US20050186577A1 (en) | 2004-02-20 | 2005-08-25 | Yixin Wang | Breast cancer prognostics |
| ES2443996T3 (en) | 2004-04-22 | 2014-02-21 | Agensys, Inc. | Antibodies and molecules derived from them that bind to STEAP-1 proteins |
| KR101268877B1 (en)* | 2004-09-01 | 2013-05-31 | 다이나박스 테크놀로지 코퍼레이션 | Methods and compositions for inhibition of innate immune responses and autoimmunity |
| EP2093297A3 (en)* | 2004-09-07 | 2009-11-18 | Telethon Institute for Child Health Research | Agents for treatment or prevention of an allergic disorder |
| CA2579705A1 (en)* | 2004-09-07 | 2006-03-16 | Telethon Institute For Child Health Research | Method of diagnosing and/or predicting the development of an allergic disorder |
| EP2332408B1 (en) | 2005-02-17 | 2013-11-13 | Biogen Idec MA Inc. | Treating neurological disorders |
| MX2007010489A (en) | 2005-02-28 | 2007-11-08 | Baxter Int | Recombinant co-expression of vitamin k epoxide reductase subunit 1 to improve vitamin k dependent protein expression. |
| ES2432564T3 (en) | 2005-05-10 | 2013-12-04 | Biogen Idec Ma Inc. | Treatment and evaluation of inflammatory disorders |
| WO2006138219A2 (en)* | 2005-06-13 | 2006-12-28 | Biogen Idec Ma Inc. | Methods of diagnosis / prognosis of inflammatory conditions |
| GB2470843B (en)* | 2005-09-01 | 2011-04-13 | Florey Howard Inst | Models and methods for the assessment of potential therapeutic agents for the modulation of NDFIP1-NEDD4 interactions |
| GB0521488D0 (en)* | 2005-10-21 | 2005-11-30 | Ares Trading Sa | Integral membrane protein |
| US7572618B2 (en) | 2006-06-30 | 2009-08-11 | Bristol-Myers Squibb Company | Polynucleotides encoding novel PCSK9 variants |
| ES2636089T3 (en) | 2006-10-27 | 2017-10-05 | Genentech, Inc. | Antibodies and immunoconjugates and uses for them |
| CA2667894A1 (en) | 2006-11-07 | 2008-05-15 | Merck & Co., Inc. | Antagonists of pcsk9 |
| US8093222B2 (en) | 2006-11-27 | 2012-01-10 | Isis Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia |
| CA2680832A1 (en) | 2007-03-27 | 2008-10-02 | Merck & Co., Inc. | Method for detecting autoprocessed, secreted pcsk9 |
| JOP20080381B1 (en) | 2007-08-23 | 2023-03-28 | Amgen Inc | Antigen Binding Proteins to Proprotein Convertase subtillisin Kexin type 9 (pcsk9) |
| EP2209896B1 (en) | 2007-10-26 | 2017-03-01 | Dynavax Technologies Corporation | Methods and compositions for inhibition of immune responses and autoimmunity |
| WO2009070350A1 (en)* | 2007-11-30 | 2009-06-04 | Siemens Healthcare Diagnostics Inc. | Adiponectin receptor fragments and methods of use |
| AR070316A1 (en) | 2008-02-07 | 2010-03-31 | Merck & Co Inc | PCSK9 ANTAGONISTS (SUBTILISINE-KEXINA TYPE 9 PROPROTEIN) |
| AR070315A1 (en) | 2008-02-07 | 2010-03-31 | Merck & Co Inc | ANTIBODIES 1B20 ANTAGONISTS OF PCSK9 |
| US8748115B2 (en) | 2008-12-12 | 2014-06-10 | Merck Sharp & Dohme Corp. | PCSK9 immunoassay |
| CN102639150A (en) | 2009-10-30 | 2012-08-15 | 默沙东公司 | AX213 and AX132 PCSK9 antagonists and variants |
| AU2010313381A1 (en) | 2009-10-30 | 2012-04-12 | Merck Sharp & Dohme Corp. | AX1 and AX189 PCSK9 antagonists and variants |
| US8940310B2 (en) | 2010-06-16 | 2015-01-27 | Dynavax Technologies Corporation | Methods of treatment using TLR7 and/or TLR9 inhibitors |
| EA025341B1 (en) | 2010-09-22 | 2016-12-30 | Алиос Биофарма, Инк. | Substituted nucleotide analogs |
| WO2012088222A2 (en) | 2010-12-21 | 2012-06-28 | The University Of North Carolina At Chapel Hill | Methods and compositions for producing active vitamin k-dependent proteins |
| EP2794630A4 (en) | 2011-12-22 | 2015-04-01 | Alios Biopharma Inc | Substituted phosphorothioate nucleotide analogs |
| WO2013142124A1 (en) | 2012-03-21 | 2013-09-26 | Vertex Pharmaceuticals Incorporated | Solid forms of a thiophosphoramidate nucleotide prodrug |
| HK1203356A1 (en) | 2012-03-22 | 2015-10-30 | 艾丽奥斯生物制药有限公司 | Pharmaceutical combinations comprising a thionucleotide analog |
| US9914769B2 (en) | 2014-07-15 | 2018-03-13 | Kymab Limited | Precision medicine for cholesterol treatment |
| US9045548B1 (en) | 2014-07-15 | 2015-06-02 | Kymab Limited | Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment |
| US8945560B1 (en) | 2014-07-15 | 2015-02-03 | Kymab Limited | Method of treating rheumatoid arthritis using antibody to IL6R |
| US9023359B1 (en) | 2014-07-15 | 2015-05-05 | Kymab Limited | Targeting rare human PCSK9 variants for cholesterol treatment |
| US8992927B1 (en) | 2014-07-15 | 2015-03-31 | Kymab Limited | Targeting human NAV1.7 variants for treatment of pain |
| US8986691B1 (en) | 2014-07-15 | 2015-03-24 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
| US8986694B1 (en) | 2014-07-15 | 2015-03-24 | Kymab Limited | Targeting human nav1.7 variants for treatment of pain |
| US8883157B1 (en) | 2013-12-17 | 2014-11-11 | Kymab Limited | Targeting rare human PCSK9 variants for cholesterol treatment |
| US8980273B1 (en) | 2014-07-15 | 2015-03-17 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
| US9017678B1 (en) | 2014-07-15 | 2015-04-28 | Kymab Limited | Method of treating rheumatoid arthritis using antibody to IL6R |
| US9034332B1 (en) | 2014-07-15 | 2015-05-19 | Kymab Limited | Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment |
| US9051378B1 (en) | 2014-07-15 | 2015-06-09 | Kymab Limited | Targeting rare human PCSK9 variants for cholesterol treatment |
| US9045545B1 (en) | 2014-07-15 | 2015-06-02 | Kymab Limited | Precision medicine by targeting PD-L1 variants for treatment of cancer |
| US9067998B1 (en) | 2014-07-15 | 2015-06-30 | Kymab Limited | Targeting PD-1 variants for treatment of cancer |
| US9682218B2 (en) | 2013-12-23 | 2017-06-20 | Carefusion 2200, Inc. | Pleurodesis device and method |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| US9139648B1 (en) | 2014-07-15 | 2015-09-22 | Kymab Limited | Precision medicine by targeting human NAV1.9 variants for treatment of pain |
| US9150660B1 (en) | 2014-07-15 | 2015-10-06 | Kymab Limited | Precision Medicine by targeting human NAV1.8 variants for treatment of pain |
| EP3471753A1 (en) | 2016-06-20 | 2019-04-24 | Kymab Limited | Anti-pd-l1 and il-2 cytokines |
| US11779604B2 (en) | 2016-11-03 | 2023-10-10 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses and methods |
| KR20230125856A (en) | 2016-12-23 | 2023-08-29 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | Gene editing of pcsk9 |
| AU2018247767B2 (en) | 2017-04-03 | 2025-01-30 | F. Hoffmann-La Roche Ag | Antibodies binding to STEAP-1 |
| US11192139B2 (en) | 2017-06-22 | 2021-12-07 | The Procter & Gamble Company | Films including a water-soluble layer and a vapor-deposited organic coating |
| WO2018237213A1 (en) | 2017-06-22 | 2018-12-27 | The Procter & Gamble Company | Films including a water-soluble layer and a vapor-deposited inorganic coating |
| WO2021207712A2 (en) | 2020-04-09 | 2021-10-14 | Verve Therapeutics, Inc. | Base editing of pcsk9 and methods of using same for treatment of disease |